AR and ERCC3 |
androgen receptor |
excision repair cross-complementation group 3 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Nucleotide Excision Repair
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Formation of transcription-coupled NER (TC-NER) repair complex
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- mRNA Capping
- RNA Polymerase I Transcription
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and TSG101 |
androgen receptor |
tumor susceptibility 101 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Assembly Of The HIV Virion
- Synthesis And Processing Of GAG, GAGPOL Polyproteins
- HIV Life Cycle
- Budding and maturation of HIV virion
- HIV Infection
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Membrane binding and targetting of GAG proteins
- Late Phase of HIV Life Cycle
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and TAF1 |
androgen receptor |
TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription
- HIV Infection
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- HIV Life Cycle
- HIV Transcription Initiation
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- RNA Polymerase II HIV Promoter Escape
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and TBP |
androgen receptor |
TATA box binding protein |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- RNA Polymerase III Transcription Initiation From Type 3 Promoter
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- RNA Polymerase II Pre-transcription Events
- HIV Life Cycle
- HIV Transcription Initiation
- NoRC negatively regulates rRNA expression
- RNA Polymerase II HIV Promoter Escape
- RNA Polymerase III Transcription Initiation
- RNA Polymerase III Transcription
- RNA Polymerase III Transcription Initiation From Type 1 Promoter
- RNA Polymerase I Transcription
- RNA Polymerase I Transcription Termination
- RNA Polymerase I Promoter Escape
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- RNA Polymerase III Transcription Initiation From Type 2 Promoter
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- RNA Polymerase III Abortive And Retractive Initiation
- RNA Polymerase II Transcription Initiation
- SIRT1 negatively regulates rRNA Expression
- Transcription of the HIV genome
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and RAN |
androgen receptor |
RAN, member RAS oncogene family |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Transcriptional regulation by small RNAs
- Metabolism of lipids and lipoproteins
- Nuclear import of Rev protein
- HIV Infection
- Regulatory RNA pathways
- Rev-mediated nuclear export of HIV RNA
- Host Interactions of HIV factors
- MicroRNA (miRNA) biogenesis
- Influenza Infection
- Interactions of Rev with host cellular proteins
- Late Phase of HIV Life Cycle
- Influenza Life Cycle
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Export of Viral Ribonucleoproteins from Nucleus
- HIV Life Cycle
- Rev-mediated nuclear export of HIV RNA
- NEP/NS2 Interacts with the Cellular Export Machinery
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and NELFCD |
androgen receptor |
negative elongation factor complex member C/D |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and XRCC5 |
androgen receptor |
X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining) |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Cytosolic sensors of pathogen-associated DNA
- HIV Infection
- Processing of DNA ends prior to end rejoining
- Integration of provirus
- Early Phase of HIV Life Cycle
- HIV Life Cycle
- Nonhomologous End-joining (NHEJ)
- STING mediated induction of host immune responses
- Double-Strand Break Repair
- IRF3-mediated induction of type I IFN
- 2-LTR circle formation
- Innate Immune System
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2H2 |
androgen receptor |
general transcription factor IIH, polypeptide 2, 44kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Nucleotide Excision Repair
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Formation of transcription-coupled NER (TC-NER) repair complex
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- mRNA Capping
- RNA Polymerase I Transcription
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and CCNH |
androgen receptor |
cyclin H |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Tat-mediated elongation of the HIV-1 transcript
- Cyclin E associated events during G1/S transition
- Formation of transcription-coupled NER (TC-NER) repair complex
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- G1/S Transition
- Mitotic G1-G1/S phases
- S Phase
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Cyclin A:Cdk2-associated events at S phase entry
- Mitotic G2-G2/M phases
- Transcription of the HIV genome
- Nucleotide Excision Repair
- RNA Polymerase II Transcription
- RNA Polymerase I Transcription Initiation
- HIV Infection
- RNA Polymerase I Promoter Clearance
- Formation of the Early Elongation Complex
- G2/M Transition
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- Cyclin A/B1 associated events during G2/M transition
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- RNA Polymerase I Transcription
- mRNA Capping
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- G1 Phase
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Cell Cycle, Mitotic
- Cyclin D associated events in G1
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2F1 |
androgen receptor |
general transcription factor IIF, polypeptide 1, 74kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- mRNA Splicing
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Influenza Life Cycle
- HIV elongation arrest and recovery
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- Influenza Viral RNA Transcription and Replication
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Processing of Capped Intron-Containing Pre-mRNA
- mRNA Capping
- mRNA Splicing - Minor Pathway
- mRNA Splicing - Major Pathway
- Influenza Infection
- Pausing and recovery of Tat-mediated HIV elongation
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Viral Messenger RNA Synthesis
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2F2 |
androgen receptor |
general transcription factor IIF, polypeptide 2, 30kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- mRNA Splicing
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Influenza Life Cycle
- HIV elongation arrest and recovery
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- Influenza Viral RNA Transcription and Replication
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Processing of Capped Intron-Containing Pre-mRNA
- mRNA Capping
- mRNA Splicing - Minor Pathway
- mRNA Splicing - Major Pathway
- Influenza Infection
- Pausing and recovery of Tat-mediated HIV elongation
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Viral Messenger RNA Synthesis
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2H1 |
androgen receptor |
general transcription factor IIH, polypeptide 1, 62kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Nucleotide Excision Repair
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Formation of transcription-coupled NER (TC-NER) repair complex
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- mRNA Capping
- RNA Polymerase I Transcription
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2H3 |
androgen receptor |
general transcription factor IIH, polypeptide 3, 34kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Nucleotide Excision Repair
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Formation of transcription-coupled NER (TC-NER) repair complex
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- mRNA Capping
- RNA Polymerase I Transcription
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and XRCC6 |
androgen receptor |
X-ray repair complementing defective repair in Chinese hamster cells 6 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Cytosolic sensors of pathogen-associated DNA
- HIV Infection
- Processing of DNA ends prior to end rejoining
- Integration of provirus
- Early Phase of HIV Life Cycle
- HIV Life Cycle
- Nonhomologous End-joining (NHEJ)
- STING mediated induction of host immune responses
- Double-Strand Break Repair
- IRF3-mediated induction of type I IFN
- 2-LTR circle formation
- Innate Immune System
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
NOS3 and NMT1 |
nitric oxide synthase 3 (endothelial cell) |
N-myristoyltransferase 1 |
- Phagosomal maturation (early endosomal stage)
- VEGFA-VEGFR2 Pathway
- eNOS activation
- Metabolism of nitric oxide
- Platelet homeostasis
- Signaling by VEGF
- VEGFR2 mediated vascular permeability
- NOSTRIN mediated eNOS trafficking
- NOSIP mediated eNOS trafficking
- Latent infection of Homo sapiens with Mycobacterium tuberculosis
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- Nitric oxide stimulates guanylate cyclase
- eNOS activation and regulation
|
- Inactivation, recovery and regulation of the phototransduction cascade
- HIV Life Cycle
- Visual phototransduction
- Activation, myristolyation of BID and translocation to mitochondria
- The phototransduction cascade
- HIV Infection
- Programmed Cell Death
- Diseases associated with visual transduction
- Late Phase of HIV Life Cycle
- Intrinsic Pathway for Apoptosis
|
- L-Arginine
- L-Citrulline
- Tetrahydrobiopterin
- Miconazole
- N,N-dimethylarginine
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- L-2-Amino-4-(Guanidinooxy)Butyric Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N\'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- 1,2,4-Triazole-Carboxamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- S,S\'-(1,4-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 7-Nitroindazole
- Ethylisothiourea
- 2-Aminothiazoline
- Se-Ethyl-Isoselenourea
- (6r,1\'r,2\'s)-5,6,7,8 Tetrahydrobiopterin
- 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine
- N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane
- Hydroxydimethylarsine Oxide
- Heme
- 7-Nitroindazole-2-Carboxamidine
- 6-Nitroindazole
- N-Omega-Hydroxy-L-Arginine
- N5-Iminoethyl-L-Ornithine
- 5,6-Cyclic-Tetrahydropteridine
- S-Ethyl-N-Phenyl-Isothiourea
- S,S\'-(1,3-Phenylene-Bis(1,2-Ethanediyl))Bis-Isothiourea
- 6s-5,6,7,8-Tetrahydrobiopterin
- S-(Dimethylarsenic)Cysteine
- L-Homoarginine
- S-Isopropyl-Isothiourea
- Nitroarginine
- 5-Nitroindazole
- N-(Chlorophenyl)-N\'-Hydroxyguanidine
- (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N\'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N\'-(3-chlorobenzyl)ethane-1,2-diamine
|
|
|
|
NR3C1 and LCK |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
LCK proto-oncogene, Src family tyrosine kinase |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- CD28 co-stimulation
- Host Interactions of HIV factors
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- TCR signaling
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- Downstream TCR signaling
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Nef Mediated CD4 Down-regulation
- Innate Immune System
- Signalling by NGF
- Generation of second messenger molecules
- Translocation of ZAP-70 to Immunological synapse
- Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
- CTLA4 inhibitory signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- CD28 dependent Vav1 pathway
- PECAM1 interactions
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- PD-1 signaling
- GPVI-mediated activation cascade
- Phosphorylation of CD3 and TCR zeta chains
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
- Dasatinib
- {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
|
|
|
NR3C1 and SLC25A4 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Integration of energy metabolism
- Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization
- HIV Infection
- Regulation of insulin secretion
- Host Interactions of HIV factors
- Mitochondrial protein import
- Interactions of Vpr with host cellular proteins
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
- Adenosine triphosphate
- Clodronate
- [3-(Dodecanoylamino)Propyl](Hydroxy)Dimethylammonium
- Carboxyatractyloside
- Cardiolipin
- Di-Stearoyl-3-Sn-Phosphatidylcholine
|
|
|
NR3C1 and FYN |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
FYN proto-oncogene, Src family tyrosine kinase |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
|
|
NR3C1 and TSG101 |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
tumor susceptibility 101 |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Assembly Of The HIV Virion
- Synthesis And Processing Of GAG, GAGPOL Polyproteins
- HIV Life Cycle
- Budding and maturation of HIV virion
- HIV Infection
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Membrane binding and targetting of GAG proteins
- Late Phase of HIV Life Cycle
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
|
|
|
NR3C1 and UBB |
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) |
ubiquitin B |
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Loss of Function of TGFBR2 in Cancer
- NF-kB is activated and signals survival
- Signaling by FGFR in disease
- Hedgehog 'off' state
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Glucose metabolism
- Toll Like Receptor TLR1:TLR2 Cascade
- Signaling by NOTCH1
- Signaling by NOTCH2
- Toll Like Receptor 5 (TLR5) Cascade
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Stabilization of p53
- Removal of licensing factors from origins
- Switching of origins to a post-replicative state
- Downregulation of ERBB2:ERBB3 signaling
- TGFBR2 MSI Frameshift Mutants in Cancer
- Signaling by NOTCH
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Spry regulation of FGF signaling
- Signaling by NOTCH
- SCF(Skp2)-mediated degradation of p27/p21
- deletions in the AMER1 gene destabilize the destruction complex
- Regulation of innate immune responses to cytosolic DNA
- Autodegradation of the E3 ubiquitin ligase COP1
- Toll Like Receptor 3 (TLR3) Cascade
- Metabolism of carbohydrates
- CDK-mediated phosphorylation and removal of Cdc6
- Cellular response to hypoxia
- Hedgehog ligand biogenesis
- p75NTR recruits signalling complexes
- Fanconi Anemia pathway
- Separation of Sister Chromatids
- HIV Infection
- APC truncation mutants have impaired AXIN binding
- Assembly of the pre-replicative complex
- Synthesis And Processing Of GAG, GAGPOL Polyproteins
- Activated TLR4 signalling
- S37 mutants of beta-catenin aren't phosphorylated
- p53-Dependent G1 DNA Damage Response
- regulation of FZD by ubiquitination
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1
- p53-Independent DNA Damage Response
- MyD88:Mal cascade initiated on plasma membrane
- Stimuli-sensing channels
- Membrane binding and targetting of GAG proteins
- p53-Independent G1/S DNA damage checkpoint
- G1/S DNA Damage Checkpoints
- Downregulation of ERBB4 signaling
- Vpu mediated degradation of CD4
- Cell death signalling via NRAGE, NRIF and NADE
- ISG15 antiviral mechanism
- Interferon Signaling
- M/G1 Transition
- p75 NTR receptor-mediated signalling
- Signaling by FGFR
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by NOTCH1 in Cancer
- TCF dependent signaling in response to WNT
- SCF-beta-TrCP mediated degradation of Emi1
- degradation of AXIN
- Degradation of GLI1 by the proteasome
- degradation of DVL
- Cell Cycle Checkpoints
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Regulation of Apoptosis
- Degradation of GLI2 by the proteasome
- Signaling by the B Cell Receptor (BCR)
- Vif-mediated degradation of APOBEC3G
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 HD Domain Mutants
- Downregulation of TGF-beta receptor signaling
- truncated APC mutants destabilize the destruction complex
- Cyclin E associated events during G1/S transition
- TGF-beta receptor signaling activates SMADs
- Regulation of PLK1 Activity at G2/M Transition
- FCERI mediated NF-kB activation
- Regulation of the Fanconi anemia pathway
- Generic Transcription Pathway
- G1/S Transition
- Toll Like Receptor 9 (TLR9) Cascade
- FBXW7 Mutants and NOTCH1 in Cancer
- IRAK1 recruits IKK complex
- Negative regulation of FGFR signaling
- truncations of AMER1 destabilize the destruction complex
- EGFR downregulation
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- IRAK2 mediated activation of TAK1 complex
- Processing-defective Hh variants abrogate ligand secretion
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- Host Interactions of HIV factors
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Fc epsilon receptor (FCERI) signaling
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Interleukin-3, 5 and GM-CSF signaling
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- M Phase
- APC truncation mutants are not K63 polyubiquitinated
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
- HIV Life Cycle
- Budding and maturation of HIV virion
- Hedgehog 'on' state
- Programmed Cell Death
- Class I MHC mediated antigen processing & presentation
- IKK complex recruitment mediated by RIP1
- MAP kinase activation in TLR cascade
- Regulation of DNA replication
- Cytokine Signaling in Immune system
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- MyD88-independent cascade
- Cell Cycle, Mitotic
- Signaling by TGF-beta Receptor Complex in Cancer
- Oxidative Stress Induced Senescence
- Activation of NF-kappaB in B cells
- Asymmetric localization of PCP proteins
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- TRAF6 mediated induction of TAK1 complex
- Negative regulators of RIG-I/MDA5 signaling
- misspliced GSK3beta mutants stabilize beta-catenin
- Hh ligand biogenesis disease
- SMAD2/3 MH2 Domain Mutants in Cancer
- T41 mutants of beta-catenin aren't phosphorylated
- Cellular Senescence
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by EGFRvIII in Cancer
- Assembly Of The HIV Virion
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- NOD1/2 Signaling Pathway
- Glycogen storage diseases
- MyD88 dependent cascade initiated on endosome
- Mitotic G1-G1/S phases
- activated TAK1 mediates p38 MAPK activation
- Regulation of mRNA stability by proteins that bind AU-rich elements
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TRIF-mediated TLR3/TLR4 signaling
- DNA Replication Pre-Initiation
- Senescence-Associated Secretory Phenotype (SASP)
- APC/C:Cdc20 mediated degradation of mitotic proteins
- TGFBR1 KD Mutants in Cancer
- S45 mutants of beta-catenin aren't phosphorylated
- Regulation of APC/C activators between G1/S and early anaphase
- Late Phase of HIV Life Cycle
- APC/C:Cdc20 mediated degradation of Cyclin B
- NOTCH2 Activation and Transmission of Signal to the Nucleus
- TCR signaling
- AMER1 mutants destabilize the destruction complex
- Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
- Interleukin-1 signaling
- APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
- PCP/CE pathway
- Mitotic G2-G2/M phases
- Adaptive Immune System
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- Ubiquitin-dependent degradation of Cyclin D
- G2/M Transition
- TGFBR1 LBD Mutants in Cancer
- Oncogene Induced Senescence
- Autodegradation of Cdh1 by Cdh1:APC/C
- Ion channel transport
- p75NTR signals via NF-kB
- Regulation of signaling by CBL
- XAV939 inhibits tankyrase, stabilizing AXIN
- Disease
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Signal Transduction
- Innate Immune System
- Synthesis of DNA
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- G1 Phase
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Ubiquitin-dependent degradation of Cyclin D1
- Activated NOTCH1 Transmits Signal to the Nucleus
- NOTCH1 Intracellular Domain Regulates Transcription
- Toll-Like Receptors Cascades
- Cyclin D associated events in G1
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Regulation of mitotic cell cycle
- Signaling by Hedgehog
- Association of licensing factors with the pre-replicative complex
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- TCF7L2 mutants don't bind CTBP
- p53-Dependent G1/S DNA damage checkpoint
- Signaling by Wnt
- AUF1 (hnRNP D0) destabilizes mRNA
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- APC/C:Cdc20 mediated degradation of Securin
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- CDK-mediated phosphorylation and removal of Cdc6
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- IRAK1 recruits IKK complex
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- RNF mutants show enhanced WNT signaling and proliferation
- Myoclonic epilepsy of Lafora
- Signaling by NOTCH1 in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- IRAK2 mediated activation of TAK1 complex
- Loss of Function of SMAD4 in Cancer
- AXIN missense mutants destabilize the destruction complex
- S Phase
- APC/C-mediated degradation of cell cycle proteins
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Glycogen synthesis
- NRIF signals cell death from the nucleus
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- SCF(Skp2)-mediated degradation of p27/p21
- Cyclin A:Cdk2-associated events at S phase entry
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Mitotic Metaphase and Anaphase
- Downstream TCR signaling
- Antigen processing: Ubiquitination & Proteasome degradation
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Orc1 removal from chromatin
- Mitotic Anaphase
- deactivation of the beta-catenin transactivating complex
- Toll Like Receptor TLR6:TLR2 Cascade
- MyD88 cascade initiated on plasma membrane
- Activated NOTCH1 Transmits Signal to the Nucleus
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Signalling by NGF
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Cytosolic sensors of pathogen-associated DNA
- beta-catenin independent WNT signaling
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Orc1 removal from chromatin
- Signaling by TGF-beta Receptor Complex
- CDT1 association with the CDC6:ORC:origin complex
- Antigen processing-Cross presentation
- ER-Phagosome pathway
- SMAD4 MH2 Domain Mutants in Cancer
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol
- Beclometasone dipropionate
- Betamethasone
- Desoximetasone
- Fluticasone Propionate
- Fluocinolone Acetonide
- Halobetasol Propionate
- Triamcinolone
- Prednisone
- Flumethasone Pivalate
- Fludrocortisone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol
- Rimexolone
- Methylprednisolone
- Clobetasol
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Ciclesonide
- Hexane-1,6-Diol
- Difluprednate
- Fluticasone furoate
|
|
|
|